Illustrative image – not actual.Dabur Pharma has planned to invest Rs.300 crore towards capacity expansion and increasing R&D activities, over the next three years. While 40 per cent of this would be utilised in expanding manufacturing units, the rest will go towards R&D.
DPL currently has manufacturing facilities in Kalyani (West Bengal), Baddi (Himachal Pradesh) and Bordon (UK) (owned by Dabur Oncology Plc, a 100 per cent subsidiary of DPL).
Dabur is now planning to set up a new plant in Baddi as well as expanding its Kalyani facility, which has already been approved by the US Food & Drug Administration.
The pharma company has also offered 1.22 crore equity shares (@Rs.54 each) to International Finance Corporation. If subscribed, IFC would have an equity share of 7.8 per cent in the company, coming at an investment of $15 million.
